SCHEMBL1127204

SCHEMBL1127204

CCc1cc(-c2ccccc2)c(C(=O)C(=O)Cl)n1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
GRIA2 P42262 7/20 0.36
GRIA4 P48058 7/20 0.36
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA3 P34903 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GABRA2 P47869 2/20 0.35
GABRB2 P47870 2/20 0.35
HSD17B10 Q99714 1/20 0.35
BRD4 O60885 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1126650 0.89 THRB (0.41) THRBSMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL15161896 0.83 CNR1 (0.38) THRBGRIA2GRIA4GABRA1GABRG2
SCHEMBL15162319 0.81 THRB (0.36) THRBSMN1; SMN2GRIA2GRIA4GABRA1
SCHEMBL1126731 0.80 MMP1 (0.41) THRBSMN1; SMN2GRIA2GRIA4GABRA1
SCHEMBL1991484 0.79 THRB (0.40) THRBSMN1; SMN2GRIA2GRIA4GABRA1
SCHEMBL15162096 0.78 THRB (0.39) THRBSMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL23488097 0.75 THRB (0.40) THRBSMN1; SMN2L3MBTL1KDM4EALDH1A1
SCHEMBL1993379 0.72 GABRA1 (0.40) THRBSMN1; SMN2GABRA1GABRG2GABRB3
SCHEMBL1127116 0.72 LMNA (0.42) THRBSMN1; SMN2L3MBTL1GABRA2GABRB2
SCHEMBL1126938 0.72 KDM4E (0.43) THRBSMN1; SMN2GABRA2GABRB2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10973821-B2 Pharmaceutical formulation F2G LIMITED (GB) 2021-04-13 US disclosed
US-20190328737-A1 PHARMACEUTICAL FORMULATION F2G LIMITED (GB) 2019-10-31 US disclosed
EP-2283006-B1 PYRROLE ANTIFUNGAL AGENTS F2G LTD (GB) 2015-02-25 EP disclosed
EP-2626361-B1 Pyrrole antifungal agents F2G LTD (GB) 2014-10-15 EP disclosed
EP-2626361-A1 Pyrrole antifungal agents F2G Limited (GB) 2013-08-14 EP disclosed
EP-2283006-A1 PYRROLE ANTIFUNGAL AGENTS F2G Limited (GB) 2011-02-16 EP disclosed
WO-2009130481-A1 PYRROLE ANTIFUNGAL AGENTS F2G LTD (GB) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190328737-A1 PHARMACEUTICAL FORMULATION DPM1, PIR, PLP2 THRB 4660/4885SMN1; SMN2 1183/4885GRIA2 3945/4885
US-10973821-B2 Pharmaceutical formulation DPM1, PIR, PFN1 THRB 4667/4885SMN1; SMN2 1058/4885GRIA2 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.